Company Filing History:
Years Active: 2021
Title: Innovations of Eduardo Butelman in Opioid Receptor Ligands
Introduction
Eduardo Butelman is a notable inventor based in New York, NY (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target kappa opioid receptors. His work focuses on addressing critical health issues such as addiction, pain, and inflammation.
Latest Patents
Eduardo Butelman holds 1 patent for his invention titled "Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation." This patent discloses compounds known as 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines, which are identified as kappa ligands. These compounds are particularly useful in treating drug dependency, pruritus, pain, and inflammation.
Career Highlights
Eduardo Butelman is affiliated with The Rockefeller University, where he conducts his research and development work. His innovative approach to drug design has positioned him as a key figure in the exploration of new therapeutic options for challenging medical conditions.
Collaborations
Throughout his career, Eduardo has collaborated with esteemed colleagues, including Mary Jeanne Kreek and Amy Ripka. These partnerships have enhanced the scope and impact of his research, contributing to advancements in the field.
Conclusion
Eduardo Butelman’s work exemplifies the intersection of innovation and healthcare, particularly through his patented compounds aimed at treating addiction and related conditions. His contributions continue to influence the development of effective therapeutic strategies.